34 results about "Domain element" patented technology

Embodiments of the present invention provide an approach for determining and / or enhancing an organization's agility across one or more computing domains. Among other things, embodiments of the present invention parse and mine organizational documents for relevant data, calculate and weight business agility scores, determine improvements to optimize domain elements to ensure optimal outcomes for customers, prioritize improvements, and / or provide organization agility information for transfer to consultants or the like. It is understood that these functions may be used independently or in conjunction with each other depending on the scope of improvement desired for a particular organization.

Specifying and / or enforcing a domain model can include generating a pictorial diagram specifying a rule within a development environment, wherein the pictorial diagram includes a first subject element specifying criteria for selecting artifacts within the development environment. The pictorial diagram can be enabled within the development environment. Responsive to an execution event, the pictorial diagram can be executed by selecting each artifact matching the criteria of the first subject element and performing the rule specified by the pictorial diagram upon each selected artifact within the development environment.

The invention discloses a system and a method of double-scalar multiplication of a streamlined elliptic curve. The system and the method realize the calculation of the scalar multiplication of an elliptic curve through a structure comprising two or three finite domain square operation devices, three finite domain multiplication devices, a finite domain addition operation device, a register set, a plurality of multipath gates and a control logic unit. The system and the method of the double-scalar multiplication of a streamlined elliptic curve have simple interface mode, greatly improved operation speed and no hardware idle time, can meet the encryption requirement of data with different widths, shorten a calculation period of an elliptic curve encryption algorithm and in parallel calculate finite domain element inversion and is quite suitable for an elliptic curve encryption system working with a high throughput rate.

The invention provides an identity authentication method of an identity card and a holder based on multi-biological characteristics. The invention mainly assists in solving potential safety hazard problems existing in a cross-application process in the prior art. An embodiment comprises the steps that: when identity card registration transaction is carried out, characteristics of fingerprints, iris information and face image of a citizen are acquired; a uniform matrix image AI, a domain element matrix image UI and an offset matrix image SI are acquired and saved respectively in a population information database and an identity card chip; when authentication is carried out, an authentication terminal acquires characteristics of the fingerprints, the iris information and the face image of an identity card holder; the uniform matrix image AI and the domain element matrix image UI are searched for in the population information database based on personal basic information PI; and identity authentication of the identity card and the holder is carried out by using three biological characteristics of the fingerprints, the iris information and the face image, the uniform matrix image AI, the domain element matrix image UI and the offset matrix image SI. According to the invention, an authentication accuracy rate and overall authentication system safety are improved and potential safety hazard existing in the cross-application process is effectively reduced.

The invention provides the preparation and application of a Her2-neu antigen-positive tumor therapeutic vaccine. Specifically, the present invention provides a fusion protein, which contains (a) tumor antigen Her2-neu extracellular domain element and (b) heat shock protein element. The invention also provides the dendritic cells sensitized with the fusion protein and the corresponding tumor therapeutic vaccine. Tests show that the vaccine of the present invention can effectively stimulate Her2-neu antigen-specific immune response in vivo, and can be effectively applied to Her2-neu positive tumors.